(Q39623662)

13 September 2017

1 reference

title

Passive Immunotherapy of Cancer in Animals and Man (English)

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A326003

19 March 2023

1 reference

S. A. Rosenberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A326003

19 March 2023

W. D. Terry

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A326003

19 March 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=326003

19 March 2023

publication date

1 January 1977

1 reference

Advances in Cancer Research

13 September 2017

1 reference

13 September 2017

25

1 reference

13 September 2017

323-388

1 reference

13 September 2017

2

27

2521

Alexander

1967

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Effect of Nucleic Acids from Immune Lymphocytes on Rat Sarcomata

19 March 2023

7

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

8

27

2535

Andrews

1967

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

9

26

1787

Atria

1966

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

"Unblocking" serum activity in vitro in the polyoma system may correlate with antitumour effects of antiserum in vivo

19 March 2023

12

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Effects of BCG on various facets of the immune response against polyoma tumors in rats

19 March 2023

14

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Regression of polyoma tumor metastasis by combined unblocking and bcg treatment-correlation with induced alterations in tumor immunity status

19 March 2023

15

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication.

19 March 2023

16

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

BCG and cancer (first of two parts).

19 March 2023

17

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

In vitro induction of a heterograft reaction: immunological parameters of the sensitization of rat lymphocytes against mouse cells in vitro

19 March 2023

19

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Treatment of Recurrent Burkitt’s Tumor with Autologous Remission Plasma

19 March 2023

21

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors

19 March 2023

23

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

25

34

1851

Bortin

1974

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Brief Communication: Graft Versus Leukemia. VI. Adoptive Immunotherapy in Combination With Chemoradiotherapy for Spontaneous Leukemia-Lymphoma in AKR Mice23

19 March 2023

27

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

New approach to immunotherapy of melanoma.

19 March 2023

28

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

THE AFRICAN LYMPHOMA: PRELIMINARY OBSERVATIONS ON RESPONSE TO THERAPY.

19 March 2023

33

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

EnhancemenT of 3LL tumor growth by autosensitized t lymphocytes independent of the host lymphatic system.

19 March 2023

34

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Local tumor immunotherapy with in vitro activated autochithonous lymphocytes

19 March 2023

35

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

The recruitment of specific effector lymphocytes by antigen-reactive lymphocytes in cell-mediated autosensitization and allosensitization reactions.

19 March 2023

36

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer

19 March 2023

38

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

39

34

3040

Davies

1974

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Preliminary experimentation with specific immunotherapy of neoplastic disease in man.I. Immediate effects of hyperimmune equine gamma globulins

19 March 2023

41

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Biological Sciences: Blood Concentration of Noradrenaline in the Dog after Intravenous Administration and the Effects of Desipramine

19 March 2023

42

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

43

32

839

Deckers

1972

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

TREATMENT OF PRIMARY FIBROSARCOMA IN THE RAT WITH IMMUNE LYMPHOCYTES

19 March 2023

44

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Passive Administration of Antiserum and Complement in Producing Anti-EL4 Cytotoxic Activity in the Serum of C57BL/6 Mice

19 March 2023

46

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

47

34

1726

Dullens

1974

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Eradication of tumour cells by successive injections of allogeneic immune and hyperimmune peritoneal cells in a murine lymphoma system

19 March 2023

48

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Therapy with antibody-coated immune and hyperimmune peritoneal cells in a murine lymphoma system

19 March 2023

49

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

52

32

141

Ellman

1972

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

55

32

997

Fass

1972

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

56

32

2427

Fass

1972

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

57

29

2177

Fefer

1969

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Adoptive chemoimmunotherapy of a moloney lymphoma

19 March 2023

58

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

The treatment of advanced bladder cancer with sensitized pig lymphocytes

19 March 2023

60

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

61

34

1074

Fidler

1974

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Experiences with lymphocyte immunotherapy in experimental tumor systems

19 March 2023

62

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Antibody formation in vitro

19 March 2023

63

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

The cure and concomitant immunization of mice bearing Ehrlich ascites tumors by treatment with an antibody-alkylating agent complex

19 March 2023

64

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Treatment of Moloney lymphoma with lethal doses of dimethyl-myleran combined with injections of haemopoietic cells

19 March 2023

65

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

In-vitro activation and reinfusion of autologous human lymphocytes

19 March 2023

66

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Cure of a mouse lymphoma with radio-iodinated antibody.

19 March 2023

70

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Antibody as carrier of chlorambucil

19 March 2023

71

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immunoradioactive agent against cancer

19 March 2023

72

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immunochemotherapy of Cancer with Chlorambucil-carrying Antibody

19 March 2023

73

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Antibody as carrier of131I in cancer diagnosis and treatment

19 March 2023

74

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immunochemotherapy of human malignant melanoma with chlorambucil-carrying antibody

19 March 2023

75

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

76

29

515

Glynn

1969

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

78

16

338

Gorer

1956

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Preparation of tumor-specific boron compounds. 1. In vitro studies using boron-labeled antibodies and elemental boron as neutron targets

19 March 2023

82

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Colony inhibition studies on blocking and non-blocking serum effects on cellular immunity to moloney sarcomas

19 March 2023

83

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Treatment of murine leukaemia with heterologous antiserum or cyclophosphamide

19 March 2023

89

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

INFECTIOUS PULMONARY DISEASE IN PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY FOR ORGAN TRANSPLANTATION

19 March 2023

90

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

An immunological approach to the therapy of cancer?

19 March 2023

91

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immunologic Response in Patients with Disseminated Cancer

19 March 2023

92

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immunotherapy for the Patient with Cancer

19 March 2023

93

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Serum-mediated leukemia cell destruction in AKR mice

19 March 2023

96

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

97

35

346

Kende

1975

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Protection of C3H mice against BP8 tumour by RNA extracted from lymph-nodes and spleens of specifically sensitized mice. Preliminary communication

19 March 2023

98

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

Tumor antigens

99

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

100

20

1561

Klein

1960

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Proceedings: Immunotherapy of malignant disease: the use of viable sensitized lymphocytes or transfer factor prepared from sensitized lymphocytes

19 March 2023

102

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Graft versus leukemia: effect of phytohemagglutinin-stimulated and normal spleen cells on Rauscher disease

19 March 2023

103

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leucocytes

19 March 2023

106

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Transfer Factor and Cellular Immune Deficiency Disease

19 March 2023

107

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

108

68

239

Lawrence

1974

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Transfer of delayed hypersensitivity to skin homografts with leukocyte extracts in man

19 March 2023

110

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

PREPARATION OF AN ANTISERUM SPECIFIC TO A SPONTANEOUS MOUSE LEUKAEMIA AFTER THE INDUCTION OF ARTIFICIAL IMMUNOLOGICAL TOLERANCE TO NORMAL MOUSE TISSUE

19 March 2023

111

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

112

26

668

Levi

1966

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Tumour Specificity and Immunological Suppression

19 March 2023

113

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

114

26

659

Levi

1966

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Osteogenic sarcoma. Immunologic parameters before and during immunotherapy with tumor-specific transfer factor

19 March 2023

115

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Increased incidence of urethane induced lung adenomata by autosensitized lymphocytes

19 March 2023

116

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

117

35

1182

Levy

1975

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

An alkylating agent-globulin conjugate with both alkylating and antibody activity.

19 March 2023

118

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Transfer factor: a potential agent for cancer therapy

19 March 2023

119

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

The effect of transfer factor therapy on tumor immunity in alveolar soft part sarcoma

19 March 2023

120

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

RNA-Induced immunity against a rat sarcoma

19 March 2023

121

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immunologic treatment of tumors

19 March 2023

122

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Feasibility of tumor immunoradiotherapy using radioiodinated antibodies to tumor-specific cell membrane antigens with emphasis on leukemias and early metastases.

19 March 2023

123

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Intralymphatic therapy with immune lymphocytes

19 March 2023

124

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Transformation of nonimmune lymph node cells to state of transplantation immunity by RNA. A preliminary report

19 March 2023

126

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

TRANSFER OF HEIGHTENED IMMUNITY TO SKIN HOMOGRAFTS BY LYMPHOID RNA.

19 March 2023

127

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Approaches to the immunological treatment of cancer in man

19 March 2023

130

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Antigens Specific for Human Lymphocytic and Myeloid Leukemia Cells: Detection by Nonhuman Primate Antiserums

19 March 2023

133

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Brief communication: melanoma-specific antibodies produced in monkeys by immunization with human melanoma cell lines.

19 March 2023

134

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

135

29

848

Mihich

1969

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer

19 March 2023

136

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immunotherapeutic suppression in transplantable solid tumours.

19 March 2023

137

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Effect on Tumour Growth in Syngeneic Recipients of Antibodies Against Tumour-Specific Antigens in Methylcholanthrene-Induced Mouse Sarcomas

19 March 2023

138

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells

19 March 2023

139

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Antitumor Effects of Antibody—Diphtheria Toxin Conjugates. III. Cyclophosphamide-Induced Immune Unresponsiveness to Conjugates2

19 March 2023

141

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Cancer Immunity—Hypothesis and Clinical Trial of Lymphocytotherapy for Malignant Diseases

19 March 2023

143

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immunotherapy of cancer. Present Status and Future Potential

19 March 2023

144

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Passive immunotherapy of leukemia and other cancer.

19 March 2023

147

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Clinical immunologic study of malignant disease: response to tumor transplants and transfer of leukocytes

19 March 2023

149

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immunotherapy of Malignant Disease

19 March 2023

150

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Rejection of polyoma virus-induced neoplasms in mice inoculated with complement and antiserum

19 March 2023

153

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Host defences to Burkitt tumour

19 March 2023

155

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

156

34

512

Nisula

1974

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Radiolabeled Antitumor Antibodies. III. Highly Iodinated and Highly Radioiodinated Antibodies2

19 March 2023

157

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Effects of dialyzable transfer factor in patients with breast cancer

19 March 2023

158

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

IMMUNOLOGY OF EXPERIMENTAL TUMORS.

19 March 2023

159

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immunotherapy of ovarian carcinoma. An experimental model

19 March 2023

161

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Serologic immunotherapy: Results and probable mechanism of action

19 March 2023

162

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Autoimmune encephalomyelitis: activation of thymus lymphocytes against syngeneic brain antigens in vitro.

19 March 2023

163

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Enzymatic activation and trapping of luminol-substituted peptides and proteins. A possible means of amplifying the cytotoxicity of anti-tumor antibodies

19 March 2023

164

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Monkey to human transfer of delayed hypersensitivity in vitro with RNA extracts.

19 March 2023

166

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

167

33

171

Pearson

1973

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Transfer of tumor immunity with ribonucleic acid

19 March 2023

170

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immune cytolysis of human tumor cells mediated by xenogeneic "immune" RNA.

19 March 2023

173

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immune RNA in the Immunotherapy of Cancer

19 March 2023

175

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

The therapy of malignant melanoma with transfer factor. A preliminary report.

19 March 2023

176

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Mediation of immunity to tumor isografts in mice by heterologous ribonucleic acid.

19 March 2023

177

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

179

31

1606

Reif

1971

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Prolongation of Survival of Tumour-bearing Animals by Transfer of “Immune” RNA with DEAE Dextran

19 March 2023

180

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Brief communication: In vivo protection against murine plasma cell tumor growth by in vitro activated syngeneic lymphocytes

19 March 2023

181

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Suppression of tumour growth in mice by a drug–antibody conjugate using a novel approach to linkage

19 March 2023

182

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Antibodies as carriers of anticancer agents.

19 March 2023

183

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Short review. Prospects for cancer immunochemotherapy

19 March 2023

184

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Augmentation of Cytotoxic Drug Action by Antibodies Directed at Cell Surface

19 March 2023

185

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

FATAL HOMOTRANSPLANTED MELANOMA: A CASE REPORT

19 March 2023

188

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Tumor regression at an untreated site during immunotherapy of an identical distant tumor

19 March 2023

189

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

191

35

1907

Schlager

1975

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Attempted adoptive immunotherapy of acute leukaemia by leucocyte transfusions

19 March 2023

194

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

196

35

3195

Segerling

1975

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

197

35

3204

Segerling

1975

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immunization of lymphocytes from cancer patients

19 March 2023

202

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

203

34

115

Sharma

1974

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Passive Immunization against Murine Lymphoma

19 March 2023

204

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immunochemotherapy of hepatoma in rats

19 March 2023

208

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

210

34

169

Smith

1974

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Possibilities and Problems of Immunologic Intervention in Cancer

19 March 2023

211

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Spontaneous regression of human melanoma: clinical and experimental studies

19 March 2023

213

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

The use of immunized pig lymph-node cells in the treatment of patients with advanced malignant disease

19 March 2023

214

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immunologically competent cells in the treatment of malignant disease

19 March 2023

215

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Bone-marrow transplantation (first of two parts).

19 March 2023

221

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

ANTIBODY PRODUCTION IN TOLERANT RABBITS TO MOUSE LYMPHOMA L-5178.

19 March 2023

223

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

226

32

1521

Ungaro

1972

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Effect of combination treatment with cyclophosphamide and isogeneic or allogeneic spleen and bone marrow cells in leukemic (l1210) mice

19 March 2023

227

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

In vitro activation of armed macrophages and the therapeutic application in mice.

19 March 2023

228

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Immune cytolysis of human tumor cells mediated by xenogeneic “immune” RNA

19 March 2023

229

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Transfer factor therapy in patients with cancer

19 March 2023

230

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

In vitro induction of tumor-specific immunity. I. Parameters of activation and cytotoxic reactivity of mouse lymphoid cells immunized in vitro against syngeneic and allogeneic plasma cell tumors

19 March 2023

231

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Cell-mediated Immunity in vitro against Syngeneic Mouse Plasma Tumour Cells

19 March 2023

232

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

INHIBITORY EFFECT OF PRE-IMMUNIZED CBA SPLEEN CELLS ON TRANSPLANTS OF A-STRAIN MOUSE MAMMARY CARCINOMA IN (CBA X A) F1 HYBRID RECIPIENTS.

19 March 2023

237

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

PRELIMINARY OBSERVATIONS ON TREATMENT OF ADVANCED CANCER BY INJECTION OF ALLOGENEIC SPLEEN CELLS

19 March 2023

238

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

THE EFFECT OF RAT SPLEEN CELLS ON TWO TRANSPLANTED MOUSE TUMOURS.

19 March 2023

239

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

THE EFFECT OF INTRAPERITONEAL INJECTION OF THORACIC DUCT LYMPHOCYTES FROM NORMAL AND IMMUNIZED RATS IN MICE INOCULATED WITH THE LANDSCHUTZ ASCITES TUMOUR.

19 March 2023

240

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Serotherapy of malignant disease

19 March 2023

241

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Cancer immunotherapy with HLA-compatible thoracic duct lymphocyte transplantation. A preliminary report.

19 March 2023

242

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

Suppression of in vivo growth of mouse myelomas by purified rabbit antibodies against mouse myeloma cells.

19 March 2023

243

1 reference

https://api.crossref.org/works/10.1016/S0065-230X(08)60637-5

19 March 2023

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=326003

19 March 2023

1 reference